{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T21:18:36Z","timestamp":1778620716966,"version":"3.51.4"},"reference-count":30,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T00:00:00Z","timestamp":1744588800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019914","name":"Flatiron Health","doi-asserted-by":"publisher","award":["GPP 2022"],"award-info":[{"award-number":["GPP 2022"]}],"id":[{"id":"10.13039\/100019914","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.clgc.2025.102362","type":"journal-article","created":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T12:25:09Z","timestamp":1744806309000},"page":"102362","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of Renal Function Eligibility Criteria on Clinical Trials and Real-World Survival Outcomes Among Patients With Metastatic Renal Cell Carcinoma"],"prefix":"10.1016","volume":"23","author":[{"given":"Xiaoliang","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jill","family":"Hasler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5681-3110","authenticated-orcid":false,"given":"Benjamin","family":"Miron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0475-0498","authenticated-orcid":false,"given":"Mengru","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anosheh","family":"Afghahi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9879-1290","authenticated-orcid":false,"given":"Trevor J.","family":"Royce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1423-5295","authenticated-orcid":false,"given":"Daniel M.","family":"Geynisman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.clgc.2025.102362_bib0001","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.ccell.2021.05.012","article-title":"Using real-word data to evaluate the effects of broadening eligibility criteria in oncology trials","volume":"39","author":"Sanz-Garcia","year":"2021","journal-title":"Cancer Cell"},{"issue":"42","key":"10.1016\/j.clgc.2025.102362_bib0002","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1200\/EDBK_350574","article-title":"Increasing inclusiveness of patient-centric clinical evidence generation in oncology: real-world data and clinical trials","volume":"42","author":"Benbow","year":"2022","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.clgc.2025.102362_bib0003","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1001\/jamaoncol.2022.7170","article-title":"Improving diversity in clinical trials by using real-world data to define eligibility criteria","volume":"9","author":"Royce","year":"2023","journal-title":"JAMA Oncol"},{"issue":"12","key":"10.1016\/j.clgc.2025.102362_bib0004","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1001\/jamaoncol.2021.4971","article-title":"Uptake and survival outcomes following immune checkpoint inhibitor therapy among trial-ineligible patients with advanced solid cancers","volume":"7","author":"Parikh","year":"2021","journal-title":"JAMA Oncol"},{"issue":"33","key":"10.1016\/j.clgc.2025.102362_bib0005","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.74.4102","article-title":"Modernizing clinical trial eligibility criteria: recommendations of the american society of clinical oncology\u2013friends of cancer research organ dysfunction, prior or concurrent malignancy, and comorbidities working group","volume":"35","author":"Lichtman","year":"2017","journal-title":"J Clin Oncol"},{"issue":"7855","key":"10.1016\/j.clgc.2025.102362_bib0006","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/s41586-021-03430-5","article-title":"Evaluating eligibility criteria of oncology trials using real-world data and AI","volume":"592","author":"Liu","year":"2021","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.clgc.2025.102362_bib0007","article-title":"Broadening eligibility criteria and diversity among patients for cancer clinical trials","volume":"3","author":"Kaur","year":"2024","journal-title":"NEJM \u00c9vid"},{"issue":"1","key":"10.1016\/j.clgc.2025.102362_bib0008","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/annonc\/mdt492","article-title":"Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials","volume":"25","author":"Heng","year":"2014","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.clgc.2025.102362_bib0009","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S1470-2045(20)30436-8","article-title":"Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial","volume":"21","author":"Powles","year":"2020","journal-title":"Lancet Oncol"},{"issue":"14","key":"10.1016\/j.clgc.2025.102362_bib0010","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.clgc.2025.102362_bib0011","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/S1470-2045(22)00290-X","article-title":"Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial","volume":"23","author":"Motzer","year":"2022","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.clgc.2025.102362_bib0012","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-001079","article-title":"Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial","volume":"5","author":"Albiges","year":"2020","journal-title":"ESMO Open"},{"issue":"5","key":"10.1016\/j.clgc.2025.102362_bib0013","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1053\/j.ackd.2021.10.008","article-title":"Renal cell cancer and chronic kidney disease","volume":"28","author":"Saly","year":"2021","journal-title":"Adv Chronic Kidney Dis"},{"issue":"0","key":"10.1016\/j.clgc.2025.102362_bib0014","first-page":"S166","article-title":"Chronic kidney disease after nephrectomy: a clinically-significant entity?","volume":"0","author":"Ellis","year":"2018","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.clgc.2025.102362_bib0015","unstructured":"Birnbaum B., Nussbaum N., Seidl-Rathkopf K., et al. Model-assisted cohort selection with bias analysis for generating large-scale cohorts from the EHR for oncology research. arXiv. doi:10.48550\/arxiv.2001.09765."},{"key":"10.1016\/j.clgc.2025.102362_bib0016","doi-asserted-by":"crossref","unstructured":"Ma X., Long L., Moon S., Adamson B.J.S., Baxi S.S. Comparison of population characteristics in real-world clinical oncology databases in the US: Flatiron Health, SEER and NPCR. medRxiv. doi:10.1101\/2020.03.16.20037143.","DOI":"10.1101\/2020.03.16.20037143"},{"issue":"1","key":"10.1016\/j.clgc.2025.102362_bib0017","first-page":"31","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"issue":"12","key":"10.1016\/j.clgc.2025.102362_bib0018","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.clgc.2025.102362_bib0019","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.clgc.2025.102362_bib0020","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1200\/JCO.23.01569","article-title":"Lenvatinib plus pembrolizumab versus sunitinib in first-line treatment of advanced renal cell carcinoma: final prespecified overall survival analysis of CLEAR, a phase III study","volume":"42","author":"Motzer","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2025.102362_bib0021","unstructured":"Shahbaz H, Rout P, Gupta M. Creatinine clearance. 2024. Accessed September 6, 2024. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK544228\/#:\u223c:text=%5B6%5D%20The%20CrCl%20rate%20approximates,approximately%2010%25%20to%2020%25."},{"issue":"Supplement 2","key":"10.1016\/j.clgc.2025.102362_bib0022","doi-asserted-by":"crossref","first-page":"S482","DOI":"10.1016\/j.jval.2020.08.476","article-title":"PCN339 deriving International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk categories using oncology Electronic Health Records (EHRS)","volume":"23","author":"Mathur","year":"2020","journal-title":"Value Health"},{"key":"10.1016\/j.clgc.2025.102362_bib0023","unstructured":"Administration F and D. FDA approves nivolumab plus ipilimumab combination for intermediate or poor-risk advanced renal cell carcinoma. April 16, 2018. Accessed September 6, 2024. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-nivolumab-plus-ipilimumab-combination-intermediate-or-poor-risk-advanced-renal-cell."},{"issue":"11","key":"10.1016\/j.clgc.2025.102362_bib0024","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1002\/cncr.34180","article-title":"Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma","volume":"128","author":"Motzer","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2025.102362_bib0025","doi-asserted-by":"crossref","first-page":"S1215","DOI":"10.1016\/j.annonc.2022.07.1567","article-title":"1464P The impact of impaired renal function on the effectiveness of first-line immuno-oncology combination therapies in metastatic renal cell carcinoma (mRCC): Results from the international metastatic RCC database consortium (IMDC)","volume":"33","author":"Navani","year":"2022","journal-title":"Ann Oncol"},{"issue":"704","key":"10.1016\/j.clgc.2025.102362_bib0026","article-title":"Prevalence of concordant and discordant comorbidity in chronic kidney disease: a large cross-sectional study","volume":"71","author":"MacRae","year":"2020","journal-title":"Br J Gen Pr"},{"issue":"4","key":"10.1016\/j.clgc.2025.102362_bib0027","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.ejca.2014.12.010","article-title":"Efficacy of sunitinib in patients with metastatic or unresectable renal cell carcinoma and renal insufficiency","volume":"51","author":"Poprach","year":"2015","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.clgc.2025.102362_bib0028","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/cncr.29773","volume":"122","author":"Kaymakcalan","year":"2016","journal-title":"Cancer"},{"issue":"16","key":"10.1016\/j.clgc.2025.102362_bib0029","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.7150\/jca.32205","article-title":"Relationship between progression-free survival and overall survival in randomized clinical trials of targeted and biologic agents in oncology","volume":"10","author":"Hess","year":"2019","journal-title":"J Cancer"},{"issue":"7","key":"10.1016\/j.clgc.2025.102362_bib0030","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.ejca.2012.02.048","article-title":"Progression free survival of first line vascular endothelial growth factor-targeted therapy is an important prognostic parameter in patients with metastatic renal cell carcinoma","volume":"48","author":"Seidel","year":"2012","journal-title":"Eur J Cancer"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767325000631?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767325000631?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T20:40:01Z","timestamp":1778618401000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767325000631"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S1558767325000631"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102362","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of Renal Function Eligibility Criteria on Clinical Trials and Real-World Survival Outcomes Among Patients With Metastatic Renal Cell Carcinoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102362","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Flatiron Health, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102362"}}